Eli Lilly’s (LLY) olomorasib was granted FDA orphan designation as a treatment of KRAS G12C-mutant NSCLC, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s LY3971297 Study: A Potential Game-Changer in Drug Safety Evaluation
- Eli Lilly’s Orforglipron Study: A Step Forward in Drug Delivery
- Eli Lilly’s New Study on LY4100511: What Investors Need to Know
- Eli Lilly’s Orforglipron Study: A Step Forward in Drug Development
- California seeks to cut Medicaid coverage for weight loss drugs, Bloomberg says